&#x27;Cancer Rates and Risks&#x27; Available

Elevating Community Oncology Care: Insights From World GU 2025

Full overall survival results with amivantamab plus lazertinib from the Asia cohort of the MARIPOSA trial will be shared at a future medical conference.

A group of community and academic oncologists exchanged ideas on optimizing therapy across different prostate, kidney, and bladder cancer populations.

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Sam S. Chang MD, MBA;Jeff Yorio, MD

SC Amivantamab Consistent With IV Formulation in EGFR-Mutated NSCLC

A group of community and academic oncologists exchanged ideas on optimizing therapy across different prostate, kidney, and bladder cancer populations.

No new safety signals were identified with subcutaneous amivantamab in EGFR-mutant NSCLC, and infusion reactions were reduced vs the IV formulation.

Roman Fabbricatore

Episode 13: Perspectives on Optimizing Community Care at World GU 2025

No new safety signals were identified with subcutaneous amivantamab in EGFR-mutant NSCLC, and infusion reactions were reduced vs the IV formulation.

Experts discuss considerations for improving the care of patients with prostate, kidney, and bladder cancer in community-based practices at World GU 2025.

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Sam S. Chang MD, MBA;Jeff Yorio, MD

Vobramitamab Duocarmazine Does Not Achieve Responses in R/R ES-SCLC

Experts discuss considerations for improving the care of patients with prostate, kidney, and bladder cancer in community-based practices at World GU 2025.

In all 9 patients treated with vobramitamab duocarmazine, no objective responses were reported.

What Makes M-Pola Superior to R-GemOx in Transplant-Ineligible LBCL?

After failing to record any objective responses in 9 patients with relapsed/refractory ES-SCLC, the phase 2 trial was terminated early.

The complete response (CR) rate was 51.4% with M-Pola vs 24.3% with R-GemOx, respectively.

Amivantamab Combo Significantly Improves OS in Asian EGFR+ NSCLC Population

Results from the SUNMO trial showed that mosunetuzumab plus polatuzumab vedotin achieved a complete response rate of 51.4% in this LBCL population.

Related Content

Elevating Community Oncology Care: Insights From World GU 2025

Full overall survival results with amivantamab plus lazertinib from the Asia cohort of the MARIPOSA trial will be shared at a future medical conference.

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Sam S. Chang MD, MBA;Jeff Yorio, MD

SC Amivantamab Consistent With IV Formulation in EGFR-Mutated NSCLC

A group of community and academic oncologists exchanged ideas on optimizing therapy across different prostate, kidney, and bladder cancer populations.

Roman Fabbricatore

Episode 13: Perspectives on Optimizing Community Care at World GU 2025

No new safety signals were identified with subcutaneous amivantamab in EGFR-mutant NSCLC, and infusion reactions were reduced vs the IV formulation.

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Sam S. Chang MD, MBA;Jeff Yorio, MD

Vobramitamab Duocarmazine Does Not Achieve Responses in R/R ES-SCLC

Experts discuss considerations for improving the care of patients with prostate, kidney, and bladder cancer in community-based practices at World GU 2025.

What Makes M-Pola Superior to R-GemOx in Transplant-Ineligible LBCL?

After failing to record any objective responses in 9 patients with relapsed/refractory ES-SCLC, the phase 2 trial was terminated early.